Provided by Tiger Trade Technology Pte. Ltd.

Oppenheimer

123.29
-0.5400-0.44%
Post-market: 123.300.0100+0.01%16:18 EDT
Volume:93.46K
Turnover:11.51M
Market Cap:1.32B
PE:13.68
High:125.44
Open:125.44
Low:121.58
Close:123.83
52wk High:125.88
52wk Low:63.81
Shares:10.71M
Float Shares:6.07M
Volume Ratio:0.85
T/O Rate:1.54%
Dividend:0.77
Dividend Rate:0.62%
EPS(TTM):9.01
EPS(LYR):13.04
ROE:10.82%
ROA:2.59%
PB:1.34
PE(LYR):9.45

Loading ...

Ulta Beauty Q2 Forecasts Appear Achievable, Conservative Guidance Update Seen, Oppenheimer Says

MT Newswires Live
·
Aug 18

Argenx price target raised to $1,100 from $1,037 at Oppenheimer

TIPRANKS
·
Aug 18

Major Brokerages' Forecasts for S&P 500 Index in 2026

Reuters
·
Aug 18

Oppenheimer Downgrades AtaiBeckley to Market Perform From Outperform

MT Newswires Live
·
Aug 18

QXO's Near Term Outlook Remains Challenging Despite Q2 Beat, Oppenheimer Says

MT Newswires Live
·
Aug 18

GE HealthCare management to meet with Oppenheimer

TIPRANKS
·
Aug 18

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says

MT Newswires Live
·
Aug 17

Oppenheimer Adjusts Guidewire Software Price Target to $200 From $180, Keeps Outperform Rating

MT Newswires Live
·
Aug 17

Guidewire price target raised to $200 from $180 at Oppenheimer

TIPRANKS
·
Aug 17

Veeva price target raised to $300 from $225 at Oppenheimer

TIPRANKS
·
Aug 17

StubHub price target lowered to $11 from $12 at Oppenheimer

TIPRANKS
·
Aug 17

Elastic price target raised to $100 from $75 at Oppenheimer

TIPRANKS
·
Aug 17

MediWound Price Target Cut to $30.00/Share from $32.00 by Oppenheimer

Dow Jones
·
Aug 15

Abeona Therapeutics is Maintained at Outperform by Oppenheimer

Dow Jones
·
Aug 15

Oppenheimer Keeps Their Buy Rating on Kyntra Bio (KYNB)

TIPRANKS
·
Aug 14

Oppenheimer Sticks to Its Hold Rating for Home Depot (HD)

TIPRANKS
·
Aug 14

Oppenheimer Adjusts PT on CrowdStrike to $250 From $187.50, Maintains Outperform Rating

MT Newswires Live
·
Aug 14

Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating

MT Newswires Live
·
Aug 14

Oppenheimer Adjusts Pelthos Therapeutics PT to $64 From $66, Maintains Outperform Rating

MT Newswires Live
·
Aug 14

Oppenheimer Remains a Buy on SentinelOne (S)

TIPRANKS
·
Aug 14